Table 2 Baseline characteristics of include trials
Author | Route of Admin-istration | Dosing Regimen (I/C) | Follow-up (M/N) | Hours Between Treatment and Delivery (T/C) | Mode of Delivery |
|---|---|---|---|---|---|
Tita 2016 | Intrave-nous | A dose of 500Â mg in 250Â ml of saline/ An identical appearing saline | 6 weeks after surgery/With 28 days or 3 months | Once the decision was made to proceed to cesarean section | Cesarean |
Oluwalana 2017 | Oral | A single dose of 2 g azithromycin/ A single dose of 2-g placebo | Postpartum 8 weeks | IQR: 3.2(1.1–8.3)/ 2.9 (1.3–6.3) | Vaginal or Cesarean |
Jyothi 2019 | Intrave-nous | A single dose of 2-g cefazolin and 500Â mg azithromycin, prior to skin incision/ A single dose of 2-g cefazolin and placebo before the skin incision | Postoperative 6 weeks | NA | Cesarean |
Subramaniam 2021 | Oral | 1-g azithromycin and placebo/ Placebo and placebo | At delivery hospitalization or up to 6 weeks after delivery | 5.6(1.7–17.9)/ 6.5 (1.6–15.1) | Vaginal or Cesarean |
Roca 2023 | Oral | Azithromycin (2-g)/ placebo | Postpartum 28 days | 1.6(0.5-4.0)/ 1.6 (0.5–4.3) | Vaginal or Cesarean |
Tita 2023 | Oral | A single dose of 2-g azithromycin/ Identical placebo | Within 6 weeks after delivery | NA | Vaginal or Cesarean |